What Does the Historical and Current Respiratory Syncytial Virus (RSV) Therapeutics Market Size Trend Indicate?
The respiratory syncytial virus (rsv) therapeutics market has seen considerable growth due to a variety of factors.
•The market of therapeutics for the respiratory syncytial virus (RSV) has seen rapid growth in recent times. The market size is predicted to rise from $1.6 billion in 2024 to $2 billion in 2025, indicating a compound annual growth rate (CAGR) of 25.0%.
It's growth in previous years can be accredited to factors such as increased disease awareness, advancements in the field of virology, susceptibility of kids, epidemic eruptions, and the progress in developing vaccines.
How Will the Respiratory Syncytial Virus (RSV) Therapeutics Market Size Evolve over the Forecast Period?
The respiratory syncytial virus (rsv) therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for significant expansion in the respiratory syncytial virus (RSV) therapeutics market in the forthcoming years. Experts predict a surge to $4.59 billion by 2029, with a compound annual growth rate (CAGR) of 23.1%.
This anticipated growth during the forecast period can be credited to developments in biologic therapies, the introduction of novel antivirals, a stronger emphasis on the elderly population, initiation of maternal immunization strategies, and worldwide research collaborations. Key trends expected to drive the market during the forecast period encompass advancements in monoclonal antibodies, the development of nasal vaccines and delivery systems, combination therapies, innovative drug delivery systems, and the availability of treatment options that can be administered at home.
What Are The Core Factors Supporting Growth In The Respiratory Syncytial Virus (RSV) Therapeutics Market?
The acceleration in the occurrence of RSV infection is a significant driver propelling the expansion of the respiratory syncytial virus (RSV) therapeutics market. RSV often leads to a broad range of respiratory infections from mild to severe, particularly affecting newborns, young children, the elderly, and individuals with weak immune systems. The surge in RSV infections necessitates the invention of groundbreaking treatments to fulfill the increasing demands and lessen the intensity of RSV-induced complications. For instance, the Centres for Disease Control and Prevention, a national health agency based in the US, reported a crucial surge in rates of RSV-associated hospitalizations among children under 4 years in September 2023, soaring from 2.0 hospitalizations per 100,000 population for the week ending August 5, 2023, to 7.0 hospitalizations per 100,000 population by August 19, 2023. Hence, the escalation in the propagation of RSV infection fuels the growth of the respiratory syncytial virus (RSV) therapeutics market.
What Are The Major Segments Within The Global Respiratory Syncytial Virus (RSV) Therapeutics Market?
The respiratory syncytial virus (RSV) therapeutics market covered in this report is segmented –
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Palivizumab: Monoclonal Antibody
2) By Ribavirin: Antiviral Medication
3) By Other Drugs: Cidofovir, Nitazoxanide, Other Experimental Or Off-Label Treatments
Pre-Book The Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Respiratory Syncytial Virus (RSV) Therapeutics Market?
The growth and popularity of a key trend in the respiratory syncytial virus (RSV) therapeutics market is linked to the development of newer, more efficient drugs and vaccines. To maintain their market dominance, the major companies within the respiratory syncytial virus (RSV) therapeutics market are actively engaging in the creation of new vaccines and drugs. In May 2023, Pfizer Inc., a pharmaceutical manufacturing firm based in the US, gained approval from the Food and Drug Administration, a federal agency in the US devoted to public health protection and promotion, for ABRYSVO. This dual RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is utilized to prevent diseases of the lower respiratory tract instigated by RSV in individuals aged 60 or older. ABRYSVO is a nonadjuvanted vaccine featuring two tailored preF proteins, designed to boost immunity against RSV A and B strains, and has demonstrated its safety and efficiency in clinical trials.
Who Are the Key Players in the Respiratory Syncytial Virus (RSV) Therapeutics Market?
Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include:
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline plc.
• Gilead Sciences Inc.
• Moderna Inc.
• Regeneron Pharmaceuticals Inc.
• Novavax AB
• Vir Biotechnology Inc.
• Lupin Limited
• Kyorin Pharmaceutical Co. Ltd.
• Bavarian Nordic A/S
• SciClone Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Hetero Healthcare Ltd
• Inovio Pharmaceuticals Inc.
• Ascletis Pharma Inc.
• NanoBio Corporation
• Vaxart Inc.
• Ark Biosciences Private Limited
• Pulmocide Ltd
What Is The Most Dominant Region In The Respiratory Syncytial Virus (RSV) Therapeutics Market?
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (RSV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
